Daratumumab in Treatment of PGNMID and C3 GN

Exclusion Criteria

• •Pregnancy
• •Hepatitis B or C, HIV
• •Multiple myeloma
• •Anemia with Hgb \< 8.5 g/dL
• •Thrombocytopenia with platelet count \< 100,000
• •Leukopenia with WBC \< 3.5
• •Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complication
• •Unable to provide consent
• •Patients receiving therapy with oral prednisone or glucocorticoid equivalent in the last 6 weeks
• •Patients who had received immunosuppressive therapy including cyclophosphamide, MMF, cyclosporine, tacrolimus or azathioprine in the last 3 months
• •Patients who received rituximab previously with CD20 count of zero at the time of enrollment